Public Health School, Medical College of Qingdao University, Qingdao, Shandong Province, P.R. China.
Qingdao Women and Children's Hospital, Qingdao University, Qingdao City, Shandong Province, P.R. China.
BMC Pregnancy Childbirth. 2023 Mar 23;23(1):202. doi: 10.1186/s12884-023-05510-y.
The joint effect of folic acid (FA) supplements and maternal pre-pregnancy body mass index (BMI) on gestational diabetes mellitus (GDM) has not been fully addressed. This study aimed to examine the joint effect of FA supplements and pre-pregnancy BMI on GDM.
Pregnant women at 4 to 14 weeks of gestation (n = 3186) were recruited during their first prenatal visit in Qingdao from May 1, 2019, to June 27, 2021. The main outcome was GDM at 24-28 weeks' gestation. Screening was based on 75 g 2-hour oral glucose tolerance (OGTT), a fasting glucose ≥ 5.1 mmol/L, or a 1-hour result ≥ 10.0 mmol/L, or a 2-hour result ≥ 8.5 mmol/L. The interactive effect of FA supplements and pre-pregnancy BMI on GDM was examined using logistic regression analysis and ratio of odds ratios (ROR) was used to compare subgroup differences.
Overall, 2,095 pregnant women were included in the analysis, and GDM incidence was 17.76%. Compared with women with pre-pregnancy BMI lower than 25.0 kg/m and FA-Sufficient supplements ≥ 400 µg/day (FA-S) population, the adjusted odds ratios (aORs) of FA-S and FA-Deficiency supplements < 400 µg/d (FA-D) were 3.57 (95% confidence interval [CI]: 2.02-6.34) and 10.82 (95% CI: 1.69-69.45) for the obese women (BMI ≥ 30.0 kg/m), and the aORs of FA-S and FA-D were 2.17 (95% CI: 1.60-2.95) and 3.27 (95% CI: 1.55-6.92) for overweight women (25.0 kg/m ≤ BMI < 30.0 kg/m). However, the risk of GDM did not differ significantly between the FA-D and the FA-S group in pre-pregnancy obese women (ROR = 2.70, 95%CI: 0.47-2.30), or overweight women (ROR = 0.66, 95%CI: 0.30-1.49). After further stratification of FA supplementation time, F-D and FA-S in obese women showed an interaction when FA supplement intake time < 3 months. However, there was no significant difference between subgroups (ROR = 1.63, 95% CI: 0.37-7.04).
Maternal pre-pregnancy BMI was associated with the incidence of GDM, the dose of FA supplementation from pre-pregnancy to early pregnancy was not found to be related to the incidence of GDM. The dosage of FA supplement was not associated with GDM irrespective of maternal pre-pregnancy BMI.
叶酸(FA)补充剂和孕妇孕前体质量指数(BMI)对妊娠期糖尿病(GDM)的联合影响尚未得到充分阐明。本研究旨在探讨 FA 补充剂和孕前 BMI 对 GDM 的联合作用。
2019 年 5 月 1 日至 2021 年 6 月 27 日,在青岛,招募了处于妊娠 4 至 14 周的孕妇(n=3186)进行首次产前检查。主要结局为 24-28 周妊娠的 GDM。筛查基于 75g 2 小时口服葡萄糖耐量(OGTT)、空腹血糖≥5.1mmol/L、1 小时结果≥10.0mmol/L 或 2 小时结果≥8.5mmol/L。使用逻辑回归分析检查 FA 补充剂和孕前 BMI 对 GDM 的交互作用,并使用比值比(ROR)比较亚组差异。
总体而言,纳入了 2095 名孕妇进行分析,GDM 的发生率为 17.76%。与孕前 BMI 低于 25.0kg/m 和 FA-充足补充剂≥400μg/天(FA-S)人群相比,肥胖女性(BMI≥30.0kg/m)中 FA-S 和 FA-缺乏补充剂<400μg/d(FA-D)的调整后比值比(aOR)分别为 3.57(95%置信区间[CI]:2.02-6.34)和 10.82(95%CI:1.69-69.45),超重女性(25.0kg/m≤BMI<30.0kg/m)中 FA-S 和 FA-D 的 aOR 分别为 2.17(95%CI:1.60-2.95)和 3.27(95%CI:1.55-6.92)。然而,在孕前肥胖女性(ROR=2.70,95%CI:0.47-2.30)或超重女性(ROR=0.66,95%CI:0.30-1.49)中,FA-D 和 FA-S 组之间的 GDM 风险无显著差异。进一步对 FA 补充时间进行分层后,肥胖女性中 FA-D 和 FA-S 在 FA 补充摄入时间<3 个月时表现出相互作用。然而,各亚组之间无显著差异(ROR=1.63,95%CI:0.37-7.04)。
孕妇孕前 BMI 与 GDM 的发生率有关,从孕前到孕早期的 FA 补充剂量与 GDM 的发生率无关。FA 补充剂的剂量与 GDM 无关,而与孕妇的孕前 BMI 无关。